ReviewRSC advances2025
Graphene-based nanozymes for revolutionizing biomedical research.
Review in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Recent advances in metal sulfide nanozymes for sensing.RSC advances · 2026Review
- Nanozyme-Driven Signal Amplification in Cancer Biosensing: Innovations Toward Precision and Point-of-Care Oncology.Micromachines · 2026Review
- Metal-Functionalized Nanozymes in Antibacterial Wound Management: Recent Advances and Future Perspectives.Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanozymes, with nanoscale dimensions and enzyme-like properties, have garnered substantial interest as they can overcome the downsides of conventional enzymes, including fragility, high cost, tedious isolation, and expensive manufacturing. Over the past decade, a diverse range of nanomaterials have demonstrated the ability to mimic enzyme-like activity by incorporating multivalent elements into nanostructures. Notably, graphene-based nanomaterials, such as graphene, graphene oxide, and reduced graphene oxide, with their precisely controlled scaffolds and electronic properties, have emerged as promising substitutes for traditional enzymes by emulating the intricately evolved catalytic centers of natural enzymes, including oxidase, peroxidase, catalase, and superoxide dismutase. The distinct electronic, mechanical, thermal, and optical properties enable graphene-based nanozymes to provide multifunctional platforms for various biomedical applications, including wound healing, tissue regeneration, cancer treatment therapies, antibacterial activity, and biosensing applications. This in-depth review examines the enzymatic features and recent advancements of graphene-based nanozymes, highlighting their significant contributions to biomedicine.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.